| Code | CSB-RA004848MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar targeting CCR9 (C-C chemokine receptor type 9), a G protein-coupled receptor that plays a critical role in lymphocyte trafficking and mucosal immunity. CCR9 mediates the migration of T cells and other immune cells to the small intestine through interaction with its ligand CCL25, making it essential for intestinal immune homeostasis. Dysregulation of CCR9 expression has been implicated in inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, as well as in certain hematological malignancies such as T-cell acute lymphoblastic leukemia where aberrant CCR9 signaling promotes disease progression.
This biosimilar is developed with reference to the antibody described in patent US20220306754A1, which characterizes therapeutic antibodies targeting CCR9 for potential intervention in immune-mediated disorders. As a research-grade reagent, this antibody serves as a valuable tool for investigating CCR9-mediated signaling pathways, studying immune cell migration mechanisms, and exploring the receptor's role in gastrointestinal immunity and cancer biology.
There are currently no reviews for this product.